SGX301
Cutaneous T-Cell Lymphoma (CTCL) - First-Line
Key Facts
About Soligenix
Soligenix operates through two core business segments: a Specialized BioTherapeutics division developing treatments for rare diseases, and a Public Health Solutions division focused on medical countermeasures against biological and chemical threats. The company's lead candidate, HyBryte™ (SGX301), has demonstrated positive Phase 3 results for cutaneous T-cell lymphoma and is positioned as a potential first-in-class photodynamic therapy. With a diversified pipeline spanning oncology, infectious diseases, and biodefense, Soligenix leverages government grants and strategic collaborations to advance its development programs while managing financial resources carefully.
View full company profile